SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Parkman Healthcare Partners LLC

CIK 0001777015 · 700 CANAL STREET, 2ND FLOOR, STAMFORD, CT, 06902 · 2035163690

Reported Value
$395M
Q3 2021
Positions
74
Filings on Record
26
2019–present window
Filed
Nov 12, 2021
original filing

Summary

Parkman Healthcare Partners LLC reported $395M in U.S.-listed holdings across 74 positions for Q3 2021.

Its largest position, DC4, represents 6.3% of the portfolio.

Compared with Q2 2021, the fund opened 11 new positions and exited 19.

Portfolio Metrics

Turnover
+18.5%
vs prior filed quarter
Top-10 Concentration
+40.8%
share of reported value
Largest Position
+6.3%
Dexcom
New / Exited
11 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $346MQ4 ’19Q1 ’20: $216MQ2 ’20: $355MQ3 ’20: $378MQ4 ’20: $390MQ4 ’20Q1 ’21: $431MQ2 ’21: $457MQ3 ’21: $395MQ4 ’21: $453MQ4 ’21Q1 ’22: $342MQ2 ’22: $272MQ3 ’22: $352MQ4 ’22: $376MQ4 ’22Q1 ’23: $460MQ2 ’23: $577MQ3 ’23: $546MQ4 ’23: $710MQ4 ’23Q1 ’24: $815MQ2 ’24: $747MQ3 ’24: $783MQ4 ’24: $751MQ4 ’24Q1 ’25: $843MQ2 ’25: $870MQ3 ’25: $959MQ4 ’25: $1.1BQ4 ’25Q1 ’26: $970Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 93.0%Other: 6.3%ADR: 0.7%
  • Common Stock · 93.0% · $367M
  • Other · 6.3% · $25M
  • ADR · 0.7% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ABBVABBVIE INCNEW+75.0K75.0K+$8M$8M
AMGNAMGEN INCNEW+20.0K20.0K+$4M$4M
AZTABROOKS AUTOMATION INC NEWNEW+40.0K40.0K+$4M$4M
RCMEURR1 RCM INCNEW+145.0K145.0K+$3M$3M
SMLRSEMLER SCIENTIFIC INCNEW+25.0K25.0K+$3M$3M
ATECALPHATEC HLDGS INCNEW+250.0K250.0K+$3M$3M
VCYTVERACYTE INCNEW+45.0K45.0K+$2M$2M
TKNOALPHA TEKNOVA INCNEW+81.4K81.4K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DC4DEXCOM INChistory →COM6.29%$25M45.5K
2ACRSACLARIS THERAPEUTICS INChistory →COM5.95%$24M1.31M
3AVTRAVANTOR INChistory →COM4.55%$18M440.0K
4UTHUNITED THERAPEUTICS CORP DELhistory →COM4.40%$17M94.3K
5IQVIQVIA HLDGS INChistory →COM4.23%$17M69.9K
6ALNYALNYLAM PHARMACEUTICALS INChistory →COM3.58%$14M75.0K
7DHRDANAHER CORPORATIONhistory →COM3.49%$14M45.3K
8SGENUSDSEAGEN INChistory →COM3.12%$12M72.7K
9CHARLES RIV LABS INTL INCCOM2.61%$10M25.0K
10NTRANATERA INChistory →COM2.54%$10M90.0K
11COOPER COS INCCOM NEW2.52%$10M24.1K
12GOSSGOSSAMER BIO INChistory →COM2.50%$10M786.9K
13PODDINSULET CORPhistory →COM2.47%$10M34.3K
14AVID BIOSERVICES INCCOM2.46%$10M450.0K
15FULCFULCRUM THERAPEUTICS INChistory →COM2.42%$10M338.8K
16HORIZON THERAPEUTICS PUB LSHS2.21%$9M79.8K
17RCUSARCUS BIOSCIENCES INChistory →COM2.09%$8M236.6K
18VTLUSDIMMUNIC INChistory →COM2.07%$8M924.1K
19ABBVABBVIE INChistory →COM2.05%$8M75.0K
20HQ8FAPOLLO ENDOSURGERY INChistory →COM1.91%$8M831.2K
21HUMHUMANA INChistory →COM1.87%$7M19.0K
22CDXSCODEXIS INChistory →COM1.68%$7M286.1K
23RGENREPLIGEN CORPhistory →COM1.46%$6M20.0K
24CTLTEURCATALENT INChistory →COM1.34%$5M39.7K
25IDXXIDEXX LABS INChistory →COM1.21%$5M7.7K
26XENEXENON PHARMACEUTICALS INChistory →COM1.20%$5M311.2K
27XRAYDENTSPLY SIRONA INChistory →COM1.18%$5M80.5K
28ISIIONIS PHARMACEUTICALS INChistory →COM1.16%$5M136.4K
29MRVIMARAVAI LIFESCIENCES HLDGS Ihistory →COM CL A1.12%$4M90.0K
30AMGNAMGEN INChistory →COM1.08%$4M20.0K
31DRNAUSDDICERNA PHARMACEUTICALS INChistory →COM1.07%$4M209.7K
32AZTABROOKS AUTOMATION INC NEWhistory →COM1.04%$4M40.0K
33PFMTUSDPERFORMANT FINL CORPCOM0.98%$4M977.3K
34KODKODIAK SCIENCES INCCOM0.89%$4M36.7K
35HBIOUSDHARVARD BIOSCIENCE INCCOM0.84%$3M475.4K
36RCMEURR1 RCM INCCOM0.81%$3M145.0K
37AXGNAXOGEN INCCOM0.80%$3M200.0K
38SMLRSEMLER SCIENTIFIC INCCOM0.79%$3M25.0K
39SUTRO BIOPHARMA INCCOM0.78%$3M163.4K
40ATECALPHATEC HLDGS INCCOM NEW0.77%$3M250.0K
41BCYCBICYCLE THERAPEUTICS PLCSPONSORED ADS0.73%$3M69.5K
42ETNBGBP89BIO INCCOM0.72%$3M145.8K
43NOTVQINOTIV INCCOM0.72%$3M97.5K
44BSFAANI PHARMACEUTICALS INCCOM0.71%$3M85.3K
45BBIOBRIDGEBIO PHARMA INCCOM0.69%$3M58.0K
46SUPNSUPERNUS PHARMACEUTICALS INCCOM0.68%$3M100.4K
47SIENUSDSIENTRA INCCOM0.64%$3M441.7K
48HCATHEALTH CATALYST INCCOM0.64%$3M50.5K
49MDGLMADRIGAL PHARMACEUTICALS INCCOM0.63%$3M31.4K
50OMGBPOUTSET MED INCCOM0.63%$2M50.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$970M90May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.1B100Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$959M91Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$870M88Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$843M91May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$751M89Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$783M93Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$747M90Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$815M99May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$710M89Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$546M102Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$577M95Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$460M83May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$376M81Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$352M89Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$272M76Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$342M80May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$453M84Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$395M74Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$457M82Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$431M83May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$390M83Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$378M84Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$355M79Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$216M66May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$346M69Feb 13, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.